Clinical Trials
10 trialsNCT03866382 2026-05-26
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT04388852 2026-05-20
DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT04709276 2026-04-06
CHAMP
Duke University
Phase 2 Active not recruiting
NCT02703623 2026-03-06
Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT03477864 2025-04-29
Stereotactic Body Radiation Therapy With REGN2810 and/or Ipilimumab Before Surgery in Treating Participants With Progressive Advanced or Oligometastatic Prostate Cancer
Thomas Jefferson University
Phase 1 Withdrawn
NCT03878524 2024-03-04
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
Phase 1 Terminated
NCT02601014 2022-02-03
STARVE-PC
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT01498978 2020-10-14
Ipilimumab in Combination With Androgen Suppression Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
OHSU Knight Cancer Institute
Phase 2 Completed
NCT00064129 2020-07-30
Ipilimumab and Sargramostim in Treating Patients With Metastatic Prostate Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT00170157 2017-05-15
Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer
Mayo Clinic
Phase 2 Completed